[Image source=Reuters Yonhap News]

[Image source=Reuters Yonhap News]

View original image



[Asia Economy Reporter Kwon Jae-hee] In Israel, there have been incidents of deaths occurring after receiving the COVID-19 vaccine on two consecutive days.


On the 29th (local time), according to local media such as The Times of Israel, an 88-year-old man in Jerusalem received the COVID-19 vaccine jointly developed by the U.S. pharmaceutical company Pfizer and the German company BioNTech, and died a few hours later.


The elderly man collapsed after returning home from vaccination and was immediately transported to the hospital by emergency medical personnel but ultimately passed away.


The hospital stated that the deceased man had been suffering from chronic complications but did not disclose specific illnesses. It remains unclear whether the cause of death was related to the vaccine.


This incident marks the second death of an elderly person vaccinated with the Pfizer vaccine in Israel.


On the previous day, the 28th, a 75-year-old man living in Beit She'an in northern Israel died at home about two hours after receiving the COVID-19 vaccine. The cause of death was reported as a heart attack.


The Israeli Ministry of Health said in an initial investigation that there appeared to be no connection between the man's death and the vaccine, noting that the deceased had suffered from illnesses such as heart disease and cancer.


Israeli media also reported that the bereaved family requested that his death not be linked to the COVID-19 vaccine.


According to the Jerusalem Post on the 28th, the Israeli public health organization 'Midat Association' stated, "Unfortunate events can occur when high-risk groups receive the vaccine."



Meanwhile, Israel began large-scale COVID-19 vaccinations targeting medical personnel and the elderly from the 20th, and by the 29th, about 500,000 people had been vaccinated.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing